GLP-1 drugs are almost single-handedly forcing employers to reconsider how they pay for their workers’ care.

Caution and survival in radiopharmaceuticals, mRNA skepticism, and more biotech news from The Readout ...

There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released ...

In today's Pharmalittle newsletter, drug pricing deals, a new cancer therapy approval, and more of the latest pharma ...

The Food and Drug Administration on Friday approved a new treatment for a rare and slow-growing cancer that causes an ...

With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...

President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.

The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from ...

A drug patent case involving Amgen is being closely watched given its potential implications for pharmaceutical patent deals ...

About 14% of employers in the U.S. have already or plan to drop coverage of GLP-1 drugs in 2027, as companies see ​rising ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...